Pramipexole

Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 33, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024

Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 33, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 33, Status: Authorised

Biotech Industry Veterans Jeff Jonas and Al Robichaud Join Cure Ventures as Partners

Retrieved on: 
Monday, January 8, 2024

Cure Ventures (“Cure”), a life sciences venture capital firm focusing on company formation around groundbreaking curative technologies, today announced the appointment of industry leaders Jeff Jonas, M.D.

Key Points: 
  • Cure Ventures (“Cure”), a life sciences venture capital firm focusing on company formation around groundbreaking curative technologies, today announced the appointment of industry leaders Jeff Jonas, M.D.
  • and Al Robichaud, Ph.D. as partners to expand the firm’s work with biotech entrepreneurs in developing therapeutics that cure life-altering diseases.
  • It’s clear to me that Cure has the chops to strategically choose its partners and elevate their work.
  • More importantly, he is about as well respected a leader as you can find in our industry,” said Dave Fallace, co-founder and managing partner at Cure Ventures.

Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 32, Status: Authorised

Retrieved on: 
Thursday, January 4, 2024

Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 32, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 32, Status: Authorised

Pharma Two B Announces Publication of Positive Phase 3 Study Results of P2B001, an Investigational Treatment for Early Parkinson’s Disease, in Movement Disorders

Retrieved on: 
Thursday, November 9, 2023

The study included 544 untreated patients with Parkinson’s disease who were randomized (2:2:2:1) to treatment with P2B001, its individual components (pramipexole-ER 0.6 mg or rasagiline-ER 0.75 mg), or marketed PramiER individually titrated to optimal dose (1.5-4.5 mg).

Key Points: 
  • The study included 544 untreated patients with Parkinson’s disease who were randomized (2:2:2:1) to treatment with P2B001, its individual components (pramipexole-ER 0.6 mg or rasagiline-ER 0.75 mg), or marketed PramiER individually titrated to optimal dose (1.5-4.5 mg).
  • Further, he stated that “P2B001 is a once-a-day treatment that requires no titration.
  • P2B001 was generally well tolerated and showed fewer sleep-related and dopaminergic adverse events in comparison to commercially used doses of pramipexole ER.
  • “We look forward to moving P2B001 forward towards an NDA submission to make this potential treatment option available to patients.”

Parkinson's Disease Market Insights, Epidemiology and Forecasts, 2032 - Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 2, 2023

The "Parkinson's Disease - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Parkinson's Disease - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of the Parkinson's disease, historical and forecasted epidemiology as well as the Parkinson's disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
  • Parkinson's disease market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Parkinson's disease market size from 2019 to 2032.
  • The majority of Diagnosed Prevalent Parkinson's Disease patients were estimated in the US followed by EU4 and the UK, and Japan.

Pharma Two B Presents Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at the MDS International Congress of Parkinson's Disease and Movement Disorders®

Retrieved on: 
Thursday, September 15, 2022

today announced that positive efficacy and safety data from its recently completed randomized, controlled Phase 3 trial of investigational P2B001 in the management of early PD will be presented at the MDS International Congress of Parkinson's Disease and Movement Disorders Sept. 15-18 in Madrid.

Key Points: 
  • today announced that positive efficacy and safety data from its recently completed randomized, controlled Phase 3 trial of investigational P2B001 in the management of early PD will be presented at the MDS International Congress of Parkinson's Disease and Movement Disorders Sept. 15-18 in Madrid.
  • The data will be presented in various formats, including a guided poster tour, an e-poster and video on the MDS Congress virtual platform, and publication in the Movement Disorders journal supplement.
  • We are pleased that the positive data from our Phase 3 study of P2B001 in early Parkinsons patients were selected for presentation at the MDS International Congress, said Dr. Sheila Oren, M.D., M.B.A., Chief Executive Officer of Pharma Two B.
  • P2B001 has the potential to be an important first line treatment option for patients with early Parkinsons disease.

Jacobson Pharma Announces FY2022 Annual Results

Retrieved on: 
Wednesday, June 29, 2022

HONG KONG, June 29, 2022 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2022 ("FY2022" or the "Reporting Period").

Key Points: 
  • HONG KONG, June 29, 2022 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2022 ("FY2022" or the "Reporting Period").
  • About Jacobson Pharma Corporation Limited (Stock Code: 2633)
    Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated and engaged in the research, development, production, sale and distribution of essential medicines and specialty drugs.
  • Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017.
  • For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com
    Copyright 2022 ACN Newswire .

Pharma Two B Presents Late-Breaker Abstract on Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at American Academy of Neurology (AAN) Annual Meeting

Retrieved on: 
Tuesday, April 5, 2022

As such, if approved, P2B001 may offer a therapy with improved benefit risk ratio between efficacy and safety for Parkinsons disease patients.

Key Points: 
  • As such, if approved, P2B001 may offer a therapy with improved benefit risk ratio between efficacy and safety for Parkinsons disease patients.
  • Of note, the low doses utilized in P2B001 are not currently available on the market and the ER rasagiline is a proprietary dosage form.
  • Pharma Two B recently reported that P2B001 met its primary and key secondary endpoints in a Phase 3 pivotal study.
  • Pharma Two B has completed a Phase 3 trial with P2B001 and is preparing to file an NDA later this year.

Global Parkinson's Disease Analysis Market Spotlight Market Report 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 25, 2022

The "Disease Analysis: Parkinson's Disease" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: Parkinson's Disease" report has been added to ResearchAndMarkets.com's offering.
  • Duopa is among the most lucrative drugs currently available in the PD market.
  • The procedure, however, is one of the most invasive in this market and comes with the usual risks of surgical complications.
  • Acadia's Nuplazid, the first and only US-approved drug for Parkinson's disease psychosis (PDP), scores well commercially in the publisher's drug assessment model.

Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson’s Disease

Retrieved on: 
Wednesday, December 15, 2021

REHOVOT, Israel, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved drugs for neurological indications, today announced that its Phase III double-blind, active-controlled study of P2B001 in early Parkinson’s disease (PD) successfully met its primary and key secondary endpoints.

Key Points: 
  • The results demonstrated both superior efficacy to components and a more favorable safety profile than treatment with standard doses of pramipexole.
  • With increased life expectancy and longer disease duration, patients will often require dopaminergic replacement therapies for many years.
  • If approved, this product will be an important new option when considering a long-term care plan for people with early-stage Parkinsons disease.
  • The companys lead product P2B001 is being investigated as a treatment for early-stage Parkinsons disease.